Contraindications
Hypersensitivity to mitomycin. Thrombocytopenia, coagulation disorders, increased bleeding tendency, acute infections, serum creatinine >1.7 mg/dL. Pregnancy and lactation.
|
Special Precautions
Patient with bone marrow suppression (platelet count <100,000/mm3, WBC <4,000/mm3, or progressive decline in either), infections (e.g. varicella infection). Phakic patients (ophthalmic). Patient receiving blood product transfusions. Renal and hepatic impairment. Patient Counselling This drug may cause weakness and lethargy, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal function (e.g. serum creatinine) prior to treatment and after each course, CBC with differential during therapy and for ≥8 weeks following therapy; liver and pulmonary function tests frequently.
|
Adverse Reactions
Significant: Bone marrow suppression (e.g. leucopenia, thrombocytopenia), renal toxicity, local ulceration and cellulitis (IV), shock or anaphylactoid reaction (e.g. itching, rash, dyspnoea, flushing), neurologic abnormalities. Ophthalmic: Corneal or scleral damage (when given in doses >0.2 mg/mL or used for longer than 2 minutes), post-operative hypotony.
Eye disorders: Retinal vein occlusion, conjunctival necrosis, haemorrhage (retinal, subconjunctival, suprachoroidal, vitreal), bleb-related infection.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, stomatitis.
General disorders and administration site conditions: Malaise, pyrexia, asthenia.
Injury, poisoning and procedural complications: Vascular pain, phlebitis, thrombus, induration or necrosis at the inj site.
Investigations: Increased serum creatinine.
Metabolism and nutrition disorders: Anorexia.
Renal and urinary disorders: Intravesical: Cystitis, bladder fibrosis or contracted bladder (e.g. pollakiuria, dysuria), calcinosis.
Skin and subcutaneous tissue disorders: Palmar-plantar erythrodysaesthesia, alopecia, pruritus, rash.
Vascular disorders: Hypertension.
Potentially Fatal: Haemolytic-uraemic syndrome, sepsis, pulmonary toxicities (e.g. pulmonary oedema, interstitial pneumonia, pulmonary fibrosis, pulmonary hypertension, pulmonary venoocclusive disease). |
Drug Interactions
Concomitant use with other chemotherapy agents (e.g. vinca alkaloids) may enhance adverse effects e.g. pulmonary toxicity, bone marrow suppression.
|
CIMS Class
|
ATC Classification
L01DC03 - mitomycin ; Belongs to the class of other cytotoxic antibiotics. Used in the treatment of cancer.
|